BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 11.12.2014

Bioequivalence Recommendations for Budesonide Extended-Release Tablets; Draft Guidance for Industry; Availability

The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Bioequivalence Recommendations for Budesonide Extended-Release Tablets." The guidance provides specific recommendations on the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for budesonide extended-release tablets.

Source: Federal Register — Food and Drug AdministrationOpen original release →